Levofloxacin/prednisolone

Drug Profile

Levofloxacin/prednisolone

Alternative Names: DE 094; Levofloxacin/prednisolone A

Latest Information Update: 20 Feb 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; Santen Pharmaceutical
  • Class Anti-inflammatories; Antiallergics; Antibacterials; Eye disorder therapies; Fluoroquinolones; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Infectious keratitis

Most Recent Events

  • 31 Jul 2010 Discontinued - Phase-II for Infectious keratitis in USA (Topical)
  • 20 Oct 2009 Levofloxacin/prednisolone is still in phase II trials for Infectious Keratitis in the US
  • 30 Jan 2008 Levofloxacin/prednisolone is still in phase II trials for Infectious keratitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top